First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma ; volume:150 ; number:6 ; day:18 ; month:6 ; year:2024 ; pages:1-11 ; date:6.2024
Journal of cancer research and clinical oncology ; 150, Heft 6 (18.6.2024), 1-11, 6.2024
- Urheber
-
Lin, Yan-Song
Li, Shuo
Yang, Xia
Guo, Rong-Ping
Huang, Yu-Hua
Bai, Kun-Hao
Weng, Jun
Yun, Jing-Ping
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00432-024-05795-2
- URN
-
urn:nbn:de:101:1-2409262128057.153193723983
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lin, Yan-Song
- Li, Shuo
- Yang, Xia
- Guo, Rong-Ping
- Huang, Yu-Hua
- Bai, Kun-Hao
- Weng, Jun
- Yun, Jing-Ping
- SpringerLink (Online service)
Ähnliche Objekte (12)
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1-negative metastatic lung adenocarcinoma: a real-world data
Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study
"PDL
Bestimmung der PD-L1-Expression auf CTCs von NSCLC-Patienten und Korrelation mit dem Therapieansprechen auf PD-(L)1-Inhibitoren
PDL kompakt
PDL kompakt
Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis
Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer
PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
WNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses
ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1-negative metastatic lung adenocarcinoma: a real-world data
Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study
"PDL
Bestimmung der PD-L1-Expression auf CTCs von NSCLC-Patienten und Korrelation mit dem Therapieansprechen auf PD-(L)1-Inhibitoren
PDL kompakt
PDL kompakt
Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis
Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer
PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
WNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses
ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1-negative metastatic lung adenocarcinoma: a real-world data
Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study
"PDL
Bestimmung der PD-L1-Expression auf CTCs von NSCLC-Patienten und Korrelation mit dem Therapieansprechen auf PD-(L)1-Inhibitoren
PDL kompakt
PDL kompakt
Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis
Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer
PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
WNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses